Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stock Report

Market Cap: US$319.3m

Eledon Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Eledon Pharmaceuticals's earnings have been declining at an average annual rate of -6.1%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

-6.06%

Earnings growth rate

22.90%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-77.79%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • Mar 24

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 07

Companies Like Eledon Pharmaceuticals (NASDAQ:ELDN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jan 28

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Summary Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment. While it's too early for large investments, a small pilot position could be warranted based on promising early data and unmet medical needs. Read the full article on Seeking Alpha
Seeking Alpha • Oct 29

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Summary Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030. Positive data obtained from investigator-sponsored phase 1/2 trial, using tegoprubart for islet cell transplantation in patients with Type 1 Diabetes. Read the full article on Seeking Alpha
Analysis Article • Mar 22

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Aug 10

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 27

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 05

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

The shares of clinical-stage biotech Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) gained 10% in post-market trading Friday after the company announced that the FDA cleared its Investigational New Drug (IND) application for kidney disease therapy tegoprubart. Phase 2a trial for the candidate is currently underway globally, targeting patients with IgA Nephropathy, which can lead to End-Stage Renal Disease, dialysis, renal transplant, and death with a progressive impact on kidney function. With the IND clearance for tegoprubart in IgA, the company plans to open U.S. trial sites for the open-label study, which will enroll up to 21 patients worldwide in each of the two dose cohorts. Following regulatory clearance in 10 countries to study tegoprubart in IgA, ELDN plans to expand the trial to two more countries, including China. Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.
Analysis Article • Aug 31

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 01

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals (NASDAQ:ELDN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application seeking to start a phase 2 trial of tegoprubart for preventing organ rejection in patients receiving a kidney transplant. The study will enroll ~120 people (60 in each group) undergoing kidney transplant  who will receive tegoprubart or the active comparator tacrolimus, sold as Prograf by Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF), as part of an immunosuppressive regimen including corticosteroids and mycophenolate mofetil or mycophenolate sodium. The trial's main goal is to assess superiority of graft function by comparing the mean estimated glomerular filtration rate (eGFR) at  12 months post-transplant in one group against the other. Secondary goals include safety, incidence of new onset diabetes, and participant and graft survival. "We believe strongly in tegoprubart’s potential to supplant CNIs in the immunosuppressive regimen of kidney transplant patients, potentially leading to reduced side effects such as diabetes and hypertension, better kidney allograft function, and a resulting longer functional life of transplanted kidneys," said Eledon CEO David-Alexandre Gros.
Seeking Alpha • Jul 18

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 1b trial of tegoprubart in patients undergoing kidney transplantation. In the study, which received clearance in Canada and the U. K., is enrolling up to 12 patients who will undergo kidney transplantation and will receive tegoprubart in combination with rabbit anti-thymocyte globulin (rATG) induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy. "We believe tegoprubart has the potential to transform the clinical management of kidney transplantation by preventing graft rejection, mitigating the multiple toxicities associated with CNIs, and ultimately improving long term outcomes," said Eledon CEO David-Alexandre Gros. In June, the U.S. Food and Drug Administration granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation.
Analysis Article • Apr 14

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 21

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

A look at the shareholders of Eledon Pharmaceuticals, Inc. ( NASDAQ:ELDN ) can tell us which group is most powerful...
Analysis Article • Dec 30

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Revenue & Expenses Breakdown

How Eledon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ELDN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-781770
31 Dec 250-461766
30 Sep 250-832067
30 Jun 250152068
31 Mar 250-191958
31 Dec 240-361952
30 Sep 240-191541
30 Jun 240-1281433
31 Mar 240-1291330
31 Dec 230-1171330
30 Sep 230-1451330
30 Jun 230-1451230
31 Mar 230-891328
31 Dec 220-881327
30 Sep 220-381426
30 Jun 220-381326
31 Mar 220-361324
31 Dec 210-351323
30 Sep 210-321320
30 Jun 210-281113
31 Mar 210-23910
31 Dec 200-2376
30 Sep 200-2164
30 Jun 200-1865
31 Mar 200-1967
31 Dec 190-1668
30 Sep 190-1679
30 Jun 190-1789
31 Mar 190-1689
31 Dec 180-1477
30 Sep 180-12133
30 Jun 180-11132
31 Mar 180-13132
31 Dec 170-11121
30 Sep 170-952
30 Jun 170-644
31 Mar 170-133
31 Dec 160-123
30 Sep 160-121

Quality Earnings: ELDN is currently unprofitable.

Growing Profit Margin: ELDN is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ELDN is unprofitable, and losses have increased over the past 5 years at a rate of 6.1% per year.

Accelerating Growth: Unable to compare ELDN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ELDN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: ELDN has a negative Return on Equity (-77.79%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 05:20
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eledon Pharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Alethia YoungCantor Fitzgerald & Co.
Pete StavropoulosCantor Fitzgerald & Co.